Abstract
Purpose
Multidisciplinary team meetings (MDMs) to address various clinical problems have become common, especially for cancer care. However, the impact of MDMs on adrenal tumor care has rarely been reported. We organized an endocrine tumor MDM including adrenal tumors in August 2014. The objective of this study was to assess the impact of our adrenal tumor MDMs on patient clinical outcomes. We compared several parameters measuring clinical outcomes before and after MDMs were instituted.
Methods
The adrenal tumor MDMs included an endocrinologists, urologists, radiologists, pathologists, and residents. We analyzed 128 consecutive cases of functioning adrenal tumors (primary aldosteronism (PA), n = 53; Cushing’s syndrome (CS), n = 24; pheochromocytoma (PCC), n = 51) who underwent surgery in Kobe University Hospital from 2008 to 2019, and compared clinical parameters before (n = 68) and after (n = 60) MDMs were instituted.
Results
Twenty-one selected cases including PA, CS, PCC, adrenocortical carcinoma, and metastatic adrenal tumor were discussed in the MDM. In the analysis of 128 cases, the difference between pre- and postoperative systolic BP (ΔBP) in patients with PA after MDMs were instituted was smaller compared with those before (p = 0.02). In CS, preoperative steroid synthesis inhibitors were used more often (33 vs. 100%, p < 0.01), postoperative plasma ACTH levels were higher (29.1 vs. 84.5 pg/mL, p < 0.01), and postoperative decrease in systolic BP was milder (p < 0.01) after MDMs were instituted. In PCC, doses of preoperative doxazosin were higher (p < 0.01) after MDMs institution. Operating time, bleeding volume, and cure rate did not differ between each tumor type.
Conclusions
These data suggest that instituting MDMs improved the perioperative management of functioning adrenal tumors.
Similar content being viewed by others
References
B.W. Lamb, H.W. Wong, C. Vincent, J.S. Green, N. Sevdalis, Teamwork and team performance in multidisciplinary cancer teams: development and evaluation of an observational assessment tool. BMJ Qual. Saf. 20, 849–856 (2011)
J. Stairmand, L. Signal, D. Sarfati, C. Jackson, L. Batten, M. Holdaway, C. Cunningham, Consideration of comorbidity in treatment decision making in multidisciplinary cancer team meetings: a systematic review. Ann. Oncol. 26, 1325–1332 (2015)
B. Pillay, A.C. Wootten, H. Crowe, N. Corcoran, B. Tran, P. Bowden, J. Crowe, A.J. Costello, The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: a systematic review of the literature. Cancer Treat. Rev. 42, 56–72 (2016)
H.O. Greer, P.J. Frederick, N.M. Falls, E.B. Tapley, K.L. Samples, K.J. Kimball, J.E. Kendrick, M.G. Conner, L. Novak, J.M. Straughn Jr, Impact of a weekly multidisciplinary tumor board conference on the management of women with gynecologic malignancies. Int. J. Gynecol. Cancer 20, 1321–1325 (2010)
S. Mori, C. Navarrete-Dechent, T.A. Petukhova, E.H. Lee, A.M. Rossi, M.A. Postow, L.A. Dunn, B.R. Roman, V.T. Yin, D.G. Coit, T.J. Hollmann et al. Tumor board conferences for multidisciplinary skin cancer management: a survey of US Cancer Centers. J. Natl. Compr. Cancer Netw. 16, 1209–1215 (2018)
J. Snyder, L. Schultz, T. Walbert, The role of tumor board conferences in neuro-oncology: a nationwide provider survey. J. Neuro-Oncol. 133, 1–7 (2017)
J.W. Funder, R.M. Carey, F. Mantero, M.H. Murad, M. Reincke, H. Shibata, M. Stowasser, W.F. Young Jr, The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 101, 1889–1916 (2016)
L.K. Nieman, B.M. Biller, J.W. Findling, M.H. Murad, J. Newell-Price, M.O. Savage, A. Tabarin; Endocrine Society, Treatment of Cushing’s syndrome: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 100, 2807–2831 (2015)
H. Fukuoka, T. Takeuchi, R. Matsumoto, H. Bando, K. Suda, H. Nishizawa, M. Takahashi, Y. Hirota, G. Iguchi, Y. Takahashi, D-dimer as a significant marker of deep vein thrombosis in patients with subclinical or overt Cushing’s syndrome. Endocr. J. 61, 1003–1010 (2014)
J.W. Lenders, Q.Y. Duh, G. Eisenhofer, A.P. Gimenez-Roqueplo, S.K. Grebe, M.H. Murad, M. Naruse, K. Pacak, W.F. Young Jr; Endocrine Society, Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99, 1915–1942 (2014)
J.J. Díez, J.C. Galofré, A. Oleaga, E. Grande, M. Mitjavila, P. Moreno, Results of a nationwide survey on multidisciplinary teams on thyroid cancer in Spain. Clin. Transl. Oncol. 21, 1319–1326 (2019)
T. Nishikawa, M. Omura, F. Satoh, H. Shibata, K. Takahashi, N. Tamura, A. Tanabe; Task Force Committee on Primary Aldosteronism, The Japan Endocrine Society, Guidelines for the diagnosis and treatment of primary aldosteronism—the Japan Endocrine Society 2009. Endocr. J. 58, 711–721 (2011)
Acknowledgements
We are grateful to Ms. Y. Souki, Ms. M. Sakoda, and Dr. M. Kimura-Koyanagi for providing excellent assistance.
Funding
Grant-in-Aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science and Technology 15K09432 (K.S.), 19K09003 (H.F.).
Author information
Authors and Affiliations
Contributions
H.F., K.S., Y.T. conceived the idea and design for this study. H.F. prepared the draft of the paper with assistance from K.S., W.O., M.F., and Y.T. M.K., T.K., M.Y., K.K., M.S., and G.I. contributed to the study design and provided clinical expertise throughout the project.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
This study was approved by the Research Ethics Committee of Kobe University Hospital (IRB# 1351).
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Fukuoka, H., Shigemura, K., Kanzawa, M. et al. The impact of adrenal tumor multidisciplinary team meetings on clinical outcomes. Endocrine 69, 519–525 (2020). https://doi.org/10.1007/s12020-020-02361-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-020-02361-x